Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ReNeuron Group (RNUGF : OTC)

• Company Description    ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 25 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: -0.63 52 Week High: $ 52 Week Low: $ Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -3.74% 12 Week 0.00% -15.89% Year To Date 0.00% -6.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Pencoed Business Park Bridgend - Pencoed,X0 CF35 5HY GBR ph: 44-20-3819-8400 fax: - reneuron@walbrookpr.com http://www.reneuron.com

• General Corporate Information    Officers Simon Dew - Chief Executive Officer Iain Ross - Executive Chairman Suzanne Hancock - Chief Operations Officer John Hawkins - Chief Financial Officer Barbara Staehelin - Senior Independent Non-Executive Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G7489A121 SIC: 8880 Fiscal Year Fiscal Year End: March Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 1.00 (0.01:1) Beta: -0.63 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.02 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©